By Natalie Foote, Director of Service Provider Operations, Science Exchange | blog.scienceexchange.com
Phenotypic Screening Pioneer Launches Novel Analgesia Panel
In this Provider Innovation Profile, we’re proud to feature Melior Discovery, a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning.
Melior’s platform evaluates compounds through up to 40 different animal models representing 14 broad therapeutic areas, potentially uncovering therapeutic efficacy that might be undetected using traditional assessments.
Recently, Melior made the news with its novel opioidTRACE® Analgesic Profiling Platform. Given the need to develop low-abuse analgesics to address the opioid crisis, Melior has configured an in vivo platform aimed at specifically profiling opioid therapeutics and related analgesics.
The opioidTRACE® platform addresses the multiple features characteristic of opioids, including rodent models that evaluate acute analgesia, chronic analgesia, respiratory depression, GI mobility, and abuse liability. In addition to opioid testing, Melior has a wide array of animal models of analgesia ranging models of acute pain to chronic neuropathy models.
Backed by Expertise in In Vivo Screening
Melior’s new panel is just the latest demonstration of the team’s unique know-how in applying “production-mode” methods for in vivo screening across multiple therapeutic areas. Its proprietary theraTRACE® platform enables rapid and cost-effective identification of new therapeutic potential by systematically screening candidates in a diverse array of validated in vivo disease models.
Fibrosis is another disease area for which Melior’s panels have exemplified the utility of in vivo phenotypic screening. Melior has validated models of liver and lung fibrosis; download the validation data for these models from the Resources section of Melior’s Science Exchange storefront.
Why Requesters are Choosing Melior for In vivo Studies
Melior’s capability directly translates to efficiencies combined with high levels of quality for their clients. Positive ratings and testimonials illustrate the benefits that attract repeat business for Melior:
- High reproducibility and predictive power of in vivo methodologies, models, and assays assuring high quality of data
- Lower overall costs resulting from the availability of highly cost effective preclinical services from Melior
- Rapid responses to requests for service and quick turnaround times for preclinical studies
- Ability to rapidly customize, design, and modify models in response to requests for specialized in vivo services or changes in protocols or unexpected results at any stage of the study
Dr. Sridharan Rajamani, Senior Research Scientist at Gilead Sciences, said that his team chose Melior Discovery because they were responsive and cost effective. “We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail,” said Dr. Rajamani. “Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.”
Interested in working with Melior Discovery? Request a quote to start the discussion.